Evidence map›Paper›PMID 35884466›Full record

ArticleCancers2022

Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors-A Retrospective Multi-Center Registry Analysis.

Viktoria Florentine Koehler, Pia Adam, Carmina Teresa Fuss, Linmiao Jiang, Elke Berg, Karin Frank-Raue, Friedhelm Raue, Eva Hoster, Thomas Knösel, Hans-Ulrich Schildhaus and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Genes · 2025
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Viktoria Florentine KoehlerDepartment of Internal Medicine IV, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-2665-1181
Pia AdamDepartment of Internal Medicine I, Division of Endocrinology/Diabetology, University of Würzburg, 97080 Würzburg, Germany.ORCID 0000-0003-3862-4639
Carmina Teresa FussDepartment of Internal Medicine I, Division of Endocrinology/Diabetology, University of Würzburg, 97080 Würzburg, Germany.
Linmiao JiangInstitute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, 81377 Munich, Germany.
Elke BergDepartment of Internal Medicine IV, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.
Karin Frank-RauePrivate Practice of Endocrinology and Nuclear Medicine, 69120 Heidelberg, Germany.
Friedhelm RauePrivate Practice of Endocrinology and Nuclear Medicine, 69120 Heidelberg, Germany.
Eva HosterInstitute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, 81377 Munich, Germany.
Thomas KnöselDepartment of Pathology, University Hospital of Munich, LMU Munich, 80337 Munich, Germany.ORCID 0000-0002-1822-0197
Hans-Ulrich SchildhausInstitute of Pathology, University Medical Center Essen, 45147 Essen, Germany.ORCID 0000-0002-9856-7050
Thomas NegeleDepartment of Surgery, Krankenhaus Martha Maria, 81479 Munich, Germany.
Udo SieboltsDepartment of Pathology, University Hospital Halle (Saale), Martin-Luther University Halle-Wittenberg, 06108 Halle, Germany.
Kerstin LorenzDepartment of Visceral, Vascular, and Endocrine Surgery, Martin-Luther University Halle-Wittenberg, 06108 Halle, Germany.
Stephanie AlleleinDivision for Specific Endocrinology, Medical Faculty, University of Düsseldorf, 40225 Düsseldorf, Germany.
Matthias SchottDivision for Specific Endocrinology, Medical Faculty, University of Düsseldorf, 40225 Düsseldorf, Germany.
Christine SpitzwegDepartment of Internal Medicine IV, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.
Matthias KroissDepartment of Internal Medicine IV, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-7628-3161
German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid Glands
University of Würzburg · DEHeinrich Heine University Düsseldorf · DELMU Klinikum · DEMartin Luther University Halle-Wittenberg · DEZimmer Biomet (Germany) · DEEssen University Hospital · DEGoethe University Frankfurt · DEMartha-Maria Hospital · DEMayo Clinic · US

Funding

Collaborative Research Center SFB 824 project C8Deutsche Forschungsgemeinschaft Priority Programme SPP1629 (SP 581/6-2)Förderprogramm Forschung und Lehre (FöFoLe) 1031The German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid Glands received grant support from Bayer, Eisai and Lilly. not applicable
6 · The paper itself

Abstract

background

methodsWe here retrospectively determined the

resultsIn total, 44/48 (92%) patients had germline or somatic

conclusions

Indexed as

medullary thyroid cancermulti-tyrosine kinase inhibitorrearranged during transfectionsurvivaltreatment outcomevariant

Identifiers

PMID35884466
PMCPMC9324961
OpenAlexW4285391772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.